X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, PharmaLogic will produce and supply doses of theranostic candidates, VMT-01 and VMT-α-NET for use in Perspective’s early-stage clinical trials, for the diagnosis and treatment of metastatic melanoma and neuroendocrine tumors, respectively.
Lead Product(s): VMT-01
Therapeutic Area: Oncology Product Name: VMT-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: PharmaLogic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 14, 2023
Details:
The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions.
Lead Product(s): VMT01
Therapeutic Area: Oncology Product Name: VMT01
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Isoray
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 06, 2023
Details:
VMT-
Lead Product(s): VMT-α-NET
Therapeutic Area: Oncology Product Name: VMT-α-NET
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Results demonstrated that the combination of [212Pb] VMT01 and immune checkpoint inhibitors induced synergistic anti-tumor effect and 43% complete tumor responses.
Lead Product(s): VMT01
Therapeutic Area: Oncology Product Name: VMT01
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
